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Abstract
Treatment of BRAF-mutant melanomas with MAP kinase pathway
inhibitors is paradigmatic of the promise of precision cancer ther-
apy but also highlights problems with drug resistance that limit
patient benefit. We use live-cell imaging, single-cell analysis, and
molecular profiling to show that exposure of tumor cells to RAF/
MEK inhibitors elicits a heterogeneous response in which some
cells die, some arrest, and the remainder adapt to drug. Drug-
adapted cells up-regulate markers of the neural crest (e.g., NGFR),
a melanocyte precursor, and grow slowly. This phenotype is tran-
siently stable, reverting to the drug-naïve state within 9 days of
drug withdrawal. Transcriptional profiling of cell lines and human
tumors implicates a c-Jun/ECM/FAK/Src cascade in de-differentia-
tion in about one-third of cell lines studied; drug-induced changes
in c-Jun and NGFR levels are also observed in xenograft and human
tumors. Drugs targeting the c-Jun/ECM/FAK/Src cascade as well as
BET bromodomain inhibitors increase the maximum effect (Emax)
of RAF/MEK kinase inhibitors by promoting cell killing. Thus, analy-
sis of reversible drug resistance at a single-cell level identifies
signaling pathways and inhibitory drugs missed by assays that
focus on cell populations.
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Introduction
Small-molecule inhibitors of MAP kinases (MAPK), such as RAF
inhibitors (e.g., vemurafenib and dabrafenib), MEK inhibitors (e.g.,
selumetinib and trametinib), or their combination, benefit a majority
of melanoma patients whose tumors carry activating V600E/K muta-
tions in the BRAF oncogene, but they commonly fail to cure disease
due to acquired resistance. Acquired resistance has been shown to
involve a diversity of oncogenic mutations in components of the
MAPK pathway (Nazarian et al, 2010; Poulikakos et al, 2011; Wagle
et al, 2011, 2014; Villanueva et al, 2013; Long et al, 2014; Van Allen
et al, 2014; Moriceau et al, 2015) or parallel signaling networks such
as the PI3K/AKT kinase cascade (Shi et al, 2014a,b). In some cases,
however, the emergence of drug-resistant clones cannot be fully
explained by known genetic mechanisms (Hugo et al, 2015). It is
thought that genetically distinct, fully drug-resistant clones arise
from tumor cells that survive the initial phases of therapy due to
drug adaptation (or tolerance) (Emmons et al, 2016). Reversible
(non-genetic) drug adaptation can be reproduced in cultured cells,
and combination therapies that block adaptive mechanisms in vitro
have shown promise in improving rates and durability of response
(Lito et al, 2013). Thus, better understanding of mechanisms
involved in drug adaptation is likely to improve the effectiveness of
melanoma therapy by delaying or controlling acquired resistance.
Adaptation to RAF inhibitors involves cell-autonomous changes
such as up-regulation or rewiring of mitogenic signaling cascades as
well as non-cell-autonomous changes in the microenvironment such
as paracrine signaling from stromal cells (Gopal et al, 2010; Lito et al,
2012; Abel et al, 2013; Hirata et al, 2015; Obenauf et al, 2015).
Understanding these mechanisms is made more complex by variabil-
ity in adaptive responses from one tumor cell line to the next (Fallahi-
Sichani et al, 2015). Differences in early adaptive signaling (involving
the PI3K/AKT, JNK/c-Jun, and NF-jB networks) exist even among
BRAFV600E cell lines with comparably high sensitivity to brief
(3–4 days of) vemurafenib treatment (Fallahi-Sichani et al, 2015).
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There is growing evidence that a reversible drug-tolerant state
associated with chromatin modifications (e.g., enhanced histone
demethylase activity) can be induced in cancer cells following drug
exposure (Sharma et al, 2010). In the case of BRAF-mutant
melanomas, a comparable vemurafenib-tolerant state has been
associated with changes in the expression of differentiation markers,
including: MITF, a key regulator of melanocyte lineage; NGFR (the
low affinity nerve growth factor receptor, also known as p75NTR or
CD271), a neural crest marker; and receptor tyrosine kinases
such as AXL, EGFR, and PDGFRb (Johannessen et al, 2013;
Konieczkowski et al, 2014; Muller et al, 2014; Sun et al, 2014;
Ravindran Menon et al, 2015; Smith et al, 2016; Tirosh et al, 2016).
Despite a wealth of data on signaling networks involved in drug
adaptation, most of our knowledge comes from studying bulk tumor
cell populations. This makes it hard to determine whether proteins
involved in adaptation are weakly active in all cells or highly active
in a subset of cells. In addition, the phenotypic consequences of
drug adaptation (e.g., the emergence of slowly proliferating cells)
have primarily been studied using fixed time assays following
1–2 weeks of drug exposure, when drug-adapted cells exhibit high
activity in multiple pro-growth signaling cascades (Ravindran
Menon et al, 2015). It therefore remains unclear how the initial
responses to drug relate to subsequent phenotypes such as cell
death or adaptation. Continuous-time, single-cell assays are required
to tease out these aspects of drug adaptation.
In this paper, we monitor the responses of BRAFV600E melanoma
cells to vemurafenib in real time using live-cell imaging and then
analyze the resulting cell states using molecular and phenotypic pro-
filing. We find that vemurafenib-treated BRAFV600E cells exhibit a
range of fates over the first 3–4 days of drug exposure; a subset of
cells undergoes apoptosis, a second subset remains arrested in the
G0/G1 phase of the cell cycle, and a third subset enters a slowly
cycling drug-resistant state. The slowly cycling resistant state is
maintained when cells are grown in the presence of drug, but it is
reversible upon 9 days of outgrowth in medium lacking drug, result-
ing in the regeneration of a population of cells exhibiting the three
behaviors of drug-naı¨ve cells. We find that adaptive resistance is
associated with de-differentiation along the melanocyte lineage and
up-regulation of neural crest markers such as NGFR. These changes
can also be detected in naı¨ve and drug-treated patient-matched
human tumors by RNA profiling and histopathology. We identify
kinase inhibitors and epigenome modifiers (e.g., BET inhibitors)
that appear to block acquisition of the slowly cycling NGFRHigh state
in cell lines and in a BRAFV600E melanoma xenograft model and
thereby increase sensitivity to vemurafenib. The data and methods
used in this paper are freely available and formatted to interchange
standards established by the NIH LINCS project (http://www.
lincsproject.org/) to promote reuse and enhance reproducibility.
Results
Live-cell imaging and single-cell analysis uncover a slowly cycling
drug-resistant state involved in adaptation to RAF inhibitors
To study the dynamics of BRAFV600E inhibition in melanoma cells,
we performed live-cell imaging on two vemurafenib-sensitive cell
lines at concentrations near the IC50 for cell killing (COLO858 and
MMACSF; IC50 ~0.1–0.5 lM; we subsequently expanded the analy-
sis to additional lines, as described below). The cells expressed a
dual cell cycle reporter (Tyson et al, 2012), comprising (i) mCherry-
geminin, a protein that is absent during G0/G1, accumulates during
S/G2/M, and disappears rapidly late in M phase concurrent with
cytokinesis and birth of daughter cells (Sakaue-Sawano et al, 2008),
and (ii) H2B-Venus, which labels chromatin, allowing mitotic chro-
mosome condensation and disintegration of nuclei during apoptosis
to be scored morphologically (Fig 1A and B). Within 24 h of expo-
sure to 1 lM vemurafenib, COLO858 and MMACSF cells were
observed to accumulate in the G0/G1 phase of the cell cycle (with
low mCherry-geminin levels and decondensed chromatin; Fig 1C
and Movie EV1). Between t = 24 and 48 h, ~50% of COLO858 and
~40% of MMACSF cells underwent apoptosis and other cells in the
population stayed arrested in G0/G1 (Fig 1C–E).
Subsequently, however, the fates of the two cell lines diverged:
MMACSF cells remained arrested, but ~20% of COLO858 cells re-
entered S phase between 48 and 84 h (highlighted in pink in Fig 1B
and C). Single-cell traces of these adapted cells showed that they
underwent division every ~65 h, as compared to doubling time of
~24 h for DMSO-treated COLO858 cells; the additional cell division
time was spent in G0/G1 (Fig 1F and Appendix Fig S1). Thus,
COLO858 cells exhibited a mixed response to vemurafenib within
the first 84 h of exposure to 1 lM vemurafenib with ~60% of cells
undergoing apoptosis (primarily between 24 and 48 h of drug expo-
sure), ~20% arresting in the G0/G1 phase of the cell cycle, and
~20% exiting arrest and entering a slowly dividing state.
Exposure of COLO858 cells to 1 lM vemurafenib for an addi-
tional ~4 days (for a total of ~8 days) revealed that cells continued
to divide slowly in the presence of drug. Approximately half of the
cells tracked from day 4 to 8 did not divide at all and the other half
divided only once, yielding an estimated doubling time of 48–96 h
(Fig 1G). The ratio of cycling versus non-cycling cells in the
population appeared to be ~1:1 throughout this period. Thus, slow
proliferation and occasional generation of non-dividing cells repre-
sent a durable state for COLO858 cells exposed to vemurafenib.
Generation of dividing adapted cells is not explained by MAPK
pathway re-activation
Incomplete inhibition or re-activation of the MAPK pathway has
been identified as a major cause of adaptive resistance to vemu-
rafenib (Lito et al, 2012). This arises because MAPK signaling is a
key regulator of proliferation in melanoma cells. We observed that
exposure of COLO858 and MMACSF cells to vemurafenib or vemu-
rafenib plus trametinib (a potent and selective inhibitor of MEK
kinase) inhibited p-ERKT202/Y204 levels by up to ~15-fold relative to
untreated cells; p-ERKT202/Y204 is a marker of MAPK pathway
activity that can be scored by single-cell imaging. Levels of
p-ERKT202/Y204 in drug-treated cells did not significantly change
during 24–72 h of treatment suggesting no recovery of MAPK signal-
ing within this period (Fig 2A and B, and Appendix Fig S2A and B).
We conclude that COLO858 cells that re-enter the cell cycle do not
re-activate the MAPK pathway. To investigate this further, we
co-stained cells for p-ERKT202/Y204 and the proliferation markers
p-RbS807/811 and Ki-67. These epitopes are present at high levels
during S/G2/M, but absent in G0/G1 phases of the cell cycle. No
significant difference in p-ERKT202/Y204 levels was observed between
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drug-treated COLO858 cells in G0/G1 (cells that scored as p-RbLow
or Ki-67Low) and cells that had re-entered cell division and were in
S/G2/M (cells that scored as p-RbHigh or Ki-67High) (Fig 2C and D,
and Appendix Fig S2C). We conclude that the re-entry of a subset
of vemurafenib-treated COLO858 cells into the cell cycle does
not require detectable re-activation of the MAPK pathway, suggest-
ing an adaptation that makes MAPK signaling less essential for
proliferation.
Adaptation reduces drug maximal effect and the incremental
benefit of raising the drug dose
To better understand how the presence of slowly dividing, drug-
adapted cells influences vemurafenib responsiveness at a population
level, as conventionally assayed, we performed sequential drug
treatment with RAF and MEK inhibitors and then counted surviving
cells (Fig 3A). First, COLO858 and MMACSF cells were exposed for
24 h to a dose of vemurafenib below the IC50 (0.01–0.32 lM) with
the goal of inducing adaptation but minimizing cell death. 1 lM
vemurafenib was then added without changing media, and cells
were grown for a further 72 h prior to counting the number of
viable and apoptotic cells. This protocol resulted in a final total drug
concentration of 1.01–1.32 lM, which is above the IC50; treatment
of cells with DMSO served as a control. We found that pre-treatment
of COLO858 cells with vemurafenib reduced cell killing by a second
bolus of drug in a dose-dependent manner (Fig 3B): A maximal 2.5-
fold increase in the number of surviving cells was observed follow-
ing 0.1 lM drug pre-treatment (relative to DMSO pre-treated cells).
No such effect was observed in MMACSF cells, in which cell viabil-
ity fell monotonically with increasing total drug concentration.
When the concentration of vemurafenib in the second bolus of drug
was varied across a range of 0–5 lM, as a means of analyzing dose–
response relationships, we observed a significant reduction in Emax
(the fraction of cells arrested or killed at maximum drug dose) and a
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Figure 1. Live-cell imaging uncovers a slowly cycling drug-resistant state involved in adaptation to RAF inhibition.
Time-lapse imaging of COLO858 and MMACSF cells stably expressing H2B-Venus and mCherry-geminin exposed to 1 lM vemurafenib or DMSO for 4–8 days.
A, B Representative images and cell cycle phases (A) and representative maps of cell lineage (B) are depicted for COLO858 under DMSO and vemurafenib conditions.
C Single-cell analysis of division and death events. Horizontal axes represent single-cell tracks with time. Division events are displayed as black or pink (in the case of
slowly cycling cells) dots. Transition from yellow to gray indicates cell death.
D Percentage of surviving and dead cells among cells tracked for 84 h.
E Percentage of division events among cells tracked during indicated time intervals.
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Data information: Data in (D–F) are presented as mean  SD using 3–4 groups of cells imaged from multiple wells (see Materials and Methods).
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decrease in Hill slope for COLO858 but not MMACSF cells
(Fig EV1A and B). Sequential dosing experiments were also
repeated using cells pre-treated with a 1:1 molar ratio of vemu-
rafenib plus trametinib. Pre-treatment of COLO858 with RAF/MEK
inhibitor combination also led to subsequent resistance (Figs 3B
and EV1C and D). We conclude that pre-treatment of COLO858 with
sublethal doses of RAF inhibitor or a RAF/MEK inhibitor combina-
tion has a significant effect on subsequent drug response primarily
by lowering maximal effect (Emax) and reducing the incremental
effect of rising drug concentration (Hill slope).
Drug-adapted, slowly cycling cells up-regulate genes associated
with a de-differentiated NGFRHigh state
To identify genes associated with acquisition of the slowly cycling,
vemurafenib-adapted state, we performed RNA sequencing
(RNA-seq) on COLO858 cells exposed to drug for 24 and 48 h; drug-
treated MMACSF cells served as a control. Genes differentially
expressed in COLO858 or MMACSF cells relative to DMSO-treated
controls were selected based on a statistical cutoff of q < 0.01.
Among these genes, we focused on the subset differing in degree of
enrichment by twofold or more between the two cell lines (see
Materials and Methods). Genes enriched in vemurafenib-treated
COLO858 cells relative to MMACSF cells comprised 479 up- and 646
down-regulated genes at 24 h and 853 up- and 713 down-regulated
genes at 48 h (Fig 4A and Dataset EV1). The top GO terms included
neural differentiation, neurogenesis, and cytoskeleton regulation
(Fig 4B and Dataset EV2): Genes involved in these processes were
enriched in COLO858 cells and reduced or unchanged in MMACSF
cells. For example, mRNA for NGFR (UniProtKB: P08138), a neural
crest marker, increased ~15-fold in vemurafenib-treated COLO858
cells, representing one of the highest fold-changes in the dataset
(q = 3 × 10–4); in contrast, NGFR fell ~fourfold in MMACSF cells
(q = 5 × 10–4). It has previously been show that cells expressing
NGFR represent an intermediate in the process by which melano-
cytes differentiate from neural crest cells (Mica et al, 2013) and
NGFR is used clinically as a histopathological marker to distinguish
desmoplastic melanomas, tumors that are negative for conventional
melanocytic markers, from other skin neoplasms (Lazova et al,
2010). In addition to promoting NGFR expression in COLO858 cells,
vemurafenib exposure led to up-regulation of neurogenesis genes
such as S100B, CNTN6, L1CAM, FYN, MAP2, and NCAM1, further
evidence that cells acquire a less differentiated, more neural crest-
like state (Fig 4A). The expression of genes involved in cell cycle
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progression also changed upon drug exposure: In both COLO858
and MMACSF cells, cell cycle genes were down-regulated by 24 h,
but in COLO858, they rose again to their original levels by 48 h
(Fig 4A and B), consistent with live-cell imaging data showing that
COLO858 cells transiently arrest and then re-enter the cell cycle.
To follow changes in NGFR protein levels in control and drug-
treated cells, we co-stained for NGFR and the proliferation marker
Ki-67; NGFR protein levels were low in drug-naı¨ve COLO858 cells
and increased up to ~sevenfold by 48 h and ~25-fold by 72 h of
vemurafenib exposure, consistent with mRNA data. In contrast,
NGFR levels fell in MMACSF cells following 48–72 h in drug
(Fig 4C). Time-course studies of COLO858 cells helped to reveal
how drug-adapted NGFRHigh cells arose. Within 24 h of vemurafenib
treatment, the population of cells shifted from a largely (> 80%)
proliferative Ki-67High/NGFRLow state to a non-mitotic Ki-67Low/
NGFRLow state (Fig 4D). Non-mitotic cells then up-regulated NGFR,
acquiring a Ki-67Low/NGFRHigh state by t = 48 h, after which they
gradually re-entered the cell cycle. By t = 72 h, > 90% of cells in
the population were NGFRHigh. Among these NGFRHigh cells, ~40%
eventually became Ki-67High, showing that they had begun to prolif-
erate. We conclude that a subset of cells exposed to vemurafenib
transiently exits the cell cycle and induces an adaptive response that
makes them drug-resistant and NGFRHigh; cells subsequently re-
enter the cell cycle and proliferate slowly.
Vemurafenib-induced de-differentiation of cells and adaptive
resistance are reversible upon drug removal
To determine whether the NGFRHigh, drug-adapted state is rever-
sible, we exposed COLO858 cells to vemurafenib (at 0.32 lM) for
48 h and then isolated NGFRHigh and NGFRLow cells by fluores-
cence-activated cell sorting (FACS). These cell populations differed
in NGFR levels ~fourfold on average (Fig 5A and Appendix Fig S3).
FACS-sorted cells were allowed to grow in fresh medium, and
samples were fixed every 24 h and the levels of NGFR and Ki-67
expression measured by immunofluorescence (Fig 5B). We
observed that NGFR levels progressively increased in the NGFRLow
pool and fell in the NGFRHigh pool, so that by day 9 average receptor
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expression levels were indistinguishable in the two pools of cells.
Return of NGFR levels to pre-treatment levels was accompanied by
an increase in Ki-67 staining showing that rapid proliferation had
resumed.
To measure vemurafenib sensitivity, NGFRHigh and NGFRLow
cells were exposed to drug, 2 days after sorting (the time required
for cells to completely re-adhere), and drug response was measured
using a conventional 3-day assay and analyzed using a recently
developed “growth rate inhibition” (GR) metric that corrects for dif-
ferences in cell proliferation rates (Hafner et al, 2016). We observed
that NGFRHigh cells were significantly less sensitive to vemurafenib
in comparison with NGFRLow cells (P = 6 × 105) (Fig 5C). In
contrast, when cells from NGFRHigh and NGFRLow pools were
allowed to grow for 9 days in the absence of drug, responsiveness
to vemurafenib was indistinguishable (Fig 5D). Moreover, when
proliferation rates were scored in freshly isolated NGFRHigh cells
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(over a 3-day period), the average cell doubling time was ~32 h as
compared to ~18 h for cells in the NGFRLow pool. (Fig 5E). Finally,
when cells that had undergone one cycle of vemurafenib-induced
NGFR up-regulation were allowed to reset to the pre-treatment state
by outgrowth in the absence of drug and then re-exposed to
vemurafenib for 48 h, NGFR was up-regulated to the same degree
as in drug-naı¨ve cells (Fig 5F).
These experiments demonstrate that the subset of vemurafenib-
treated COLO858 cells able to acquire a slowly dividing NGFRHigh
phenotype is more drug-resistant than the subset of cells in the same
initial population that remains NGFRLow. As expected, the
magnitude of the difference in drug resistance and growth rate
observed in studies of FACS-sorted cells was smaller than in live-cell
imaging experiments. This is because analysis of sorted cells
involves waiting for cells to re-adhere in the absence of drug; during
this period, the adapted phenotype relaxes to the pre-treatment
state. In contrast, in live-cell studies, cells are continuously exposed
to drug and the adapted phenotype is maintained. Overall, we
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conclude that the vemurafenib-induced, slowly cycling, NGFRHigh
state is transiently stable allowing NGFRHigh and NGFRLow cells to
inter-convert on a time scale of about a week in culture. Such
behavior is inconsistent with a genetic difference between the two
populations of cells, but similar to the transiently heritable cell-
to-cell variability previously shown to play a role in cellular
response to pro-apoptotic ligands (Flusberg et al, 2013) and other
small-molecule drugs (Cohen et al, 2008; Sharma et al, 2010).
Induction of an NGFRHigh state involves extracellular matrix (ECM)
components, focal adhesion, and the AP1 transcription factor c-Jun
To identify biochemical pathways involved in NGFR up-regulation,
we performed pathway enrichment analysis on genes differentially
regulated in vemurafenib-treated COLO858 and MMACSF cells. Cell
adhesion, ECM remodeling, and epithelial-to-mesenchymal transition
(EMT) were among the top enriched pathways (Fig EV2 and Dataset
EV2). Genes up-regulated in vemurafenib-treated COLO858 cells
included the ECM components thrombospondin-1 (THBS1; TSP-1;
UniProtKB: P07996), an adhesive glycoprotein that mediates cell–cell
and cell–ECM interactions, the laminin subunits LAMA1 and LAMC1
(UniProtKB: P25391 and P11047), CCN signaling protein NOV
(Perbal, 2004) (UniProtKB: P48745), and several integrin family
receptors (Fig 6A and B). Gene set enrichment analysis (GSEA)
showed that similar molecules and pathways accompany increased
NGFR expression in 25 BRAFV600E melanoma cell lines found in the
Cancer Cell Line Encyclopedia (CCLE) and 128 BRAFV600E melanoma
biopsies in The Cancer Genome Atlas (TCGA) (Fig 6C).
To identify potential transcriptional regulators of genes up-
regulated in the NGFRHigh state, we used DAVID (http://
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Figure 6. The NGFRHigh state involves extracellular matrix (ECM) components, focal adhesion, and the AP1 transcription factor c-Jun.
A, B Top differentially regulated genes encoding secreted proteins (A) and cell surface receptors (B) between COLO858 and MMACSF cells.
C Ranked GSEA plots of top KEGG pathways significantly correlated with NGFR expression in 25 BRAFV600E melanoma cell lines from the CCLE (top) and tumor
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D, E A list of transcription factor candidates predicted (by DAVID; see Materials and Methods) to regulate differentially expressed genes between vemurafenib-treated
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F Quantified Western blot measurements (see Materials and Methods) for thrombospondin-1 (THBS1; TSP-1), integrin b1, and p-FAKY397 in COLO858 and MMACSF
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Data information: Data in (F, G) are presented as mean  SD.
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david.abcc.ncifcrf.gov) (Fig 6D) and then examined expression
levels for the top 10 transcription factor candidates (Fig 6E).
DAVID identified the AP1 family of transcription factors as the
top candidates for regulators of the adapted state in COLO858
cells (P  1020) (Fig 6D). Moreover, JUN—which encodes the
AP1 transcription factor c-Jun—was the most differentially
enriched candidate: In COLO858, it was up-regulated ~ninefold
within 24 h and ~23-fold within 48 h of exposure to vemurafenib,
but changed at most ~twofold in MMACSF cells within 48 h of
treatment (Fig 6E). When we focused DAVID and differential
expression analysis specifically on receptors and secreted/ECM
proteins, AP1 factors and JUN were again predicted to be key
differential regulators of vemurafenib response in COLO858 and
MMACSF cells (Fig EV3A).
To investigate the involvement of ECM proteins and receptors in
drug adaptation, we performed Western blotting on extracts from
COLO858 and MMACSF cells, focusing on the subset of genes for
which antibodies are available: TSP-1, integrin b1 (a subunit of a
cell adhesion receptor that binds to TSP-1), and an activating
phosphorylation site on the focal adhesion kinase (p-FAKY397).
Following 48 h in 0.2 or 1 lM vemurafenib, p-FAK levels (normal-
ized to the levels of HSP90a/b) increased ~3.5-fold in COLO858
cells relative to DMSO-treated cells, whereas they fell slightly
(~25%) in MMACSF cells (Figs 6F and EV3B). TSP-1 levels (also
normalized to HSP90a/b levels) increased by ~25-fold in COLO858
cells but only ~twofold in MMACSF cells. Integrin b1 was induced
> fivefold in COLO858 cells, but only ~twofold in MMACSF cells.
Both c-Jun and p-c-JunS73 (the active state of the protein) were
substantially elevated by vemurafenib treatment (up to ~12-fold
and ~threefold, respectively) in COLO858 cells but down-regulated
(by ~50%) in MMACSF cells (Fig 6G). Thus, differences detected at
the level of mRNA were reflected in the levels and activities of the
corresponding proteins.
To obtain functional data on proteins implicated in the drug-
adapted state, we depleted JUN or PTK2 (the FAK gene) in COLO858
cells by siRNA. Depletion of either gene significantly reduced
vemurafenib-induced NGFR up-regulation (by ~70%) and increased
sensitivity to vemurafenib as compared to cells transfected with
control siRNA (Fig 7A). NGFR knockdown, however, did not reduce
cell viability nor did exposure of cells to NGF, an NGFR ligand (Fig
EV3C). Thus, NGFR appears to be a marker of the vemurafenib-
resistant cell state rather than a regulator of drug resistance. In
contrast, siRNA experiments directly implicate c-Jun and FAK in
drug adaptation.
Concurrent inhibition of RAF/MEK signaling and a putative
c-Jun/FAK/Src cascade overcomes vemurafenib resistance in
NGFRHigh cells
To begin to identify signaling proteins involved in acquisition of an
NGFRHigh, drug-adapted state, we exposed COLO858 cells to
vemurafenib in combination with a range of small-molecule kinase
inhibitors, including defactinib and PF562271, two compounds that
target FAK; JNK-IN-8, a selective inhibitor of c-Jun N-terminal
kinases (JNK); and dasatinib and saracatinib, two inhibitors of Src
family non-receptor tyrosine kinases that function downstream of
FAK (and other receptor tyrosine kinases); see Fig 7 for details on
drug dosing and nominal target information. When COLO858 cells
were treated with these drugs and vemurafenib at 0.32 or 1 lM for
48 h, induction of NGFR was reduced from threefold to fivefold to
less than 1.5-fold (and in some cases to levels below those of drug-
naı¨ve cells; Fig 7B). In contrast, exposing COLO858 cells to trame-
tinib plus vemurafenib enhanced NGFR induction as compared to
vemurafenib alone (Fig 7B). Thus, kinases targeted by the approved
drug dasatinib (Sprycel), investigational drugs defactinib, and
saracatinib as well as tool compounds PF562271 and JNK-IN-8
are involved in vemurafenib-induced NGFR up-regulation. Super-
induction of NGFR by vemurafenib plus trametinib shows that
MAPK signaling is a negative regulator of this process
(Appendix Fig S4A).
To better understand the effects of kinase inhibitors on
vemurafenib adaptation, we measured NGFR and Ki-67 in single
cells by imaging. Assays were performed across doses, and data
were z-scored and visualized as a 2D landscape (Fig 7C). This
showed that the effects of JNK, FAK, and Src inhibitors in vemu-
rafenib-treated cells (green arrow) were orthogonal to the effects of
trametinib (red arrow): Whereas the fraction of NGFRHigh cells rose
as the fraction of Ki-67High cells fell with trametinib, with JNK, FAK,
or Src inhibitors both NGFR and Ki-67 were suppressed (Fig 7C).
Co-drugging COLO858 cells with trametinib reduced p-ERKT202/Y204
levels, but co-drugging with JNK, FAK, or Src inhibitors had no
effect on p-ERKT202/Y204 levels relative to vemurafenib alone
(Fig EV4). We conclude that whereas trametinib acts to enhance
both the therapeutic effect of vemurafenib (i.e., inhibition of
proliferation) and its counter-therapeutic effect (i.e., induction of
the NGFRHigh state), JNK, FAK, or Src inhibitors have orthogonal
activities that reduce drug adaptation.
The biological significance of these findings was confirmed by
dose–response studies showing that combining vemurafenib with
JNK, FAK, or Src inhibitors increased killing of COLO858 but not
MMACSF cells (Fig 7D and Appendix Fig S4B). Moreover, the
effectiveness of JNK, FAK, or Src inhibitors rose when MAPK signal-
ing was more fully inhibited by a combination of vemurafenib and
trametinib (Fig 7D; right panel). The primary effect of combining
MAPK inhibitors with drugs such as dasatinib or saracatinib was an
increase in Emax and a reduction in the fraction of surviving cells. In
Fig 7D, log–log drug dose–response plots highlight that co-drugging
primarily affected the 1–10% of BRAFV600E cells that survived MAPK
inhibitors; such differences were much less obvious when using log-
linear dose–response plots conventionally used to score interaction.
We conclude that drugs targeting kinases that lie within pathways
identified by gene sent enrichment analysis as up-regulated in
vemurafenib-treated COLO858 cells substantially increase cell
killing.
A screen identifies chromatin modifications as additional
contributors to the NGFRHigh state
The acquisition of transiently heritable states in drug-treated
melanoma cells is reminiscent of reversible drug tolerance previ-
ously shown to involve chromatin modifications sensitive to
HDAC inhibition (Sharma et al, 2010; Ravindran Menon et al,
2015). We therefore performed a focused screen with a library of
small-molecule inhibitors of epigenome-modifying enzymes to
identify those that reduced NGFR induction by vemurafenib.
COLO858 cells were exposed for 48 h to a sublethal dose of
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vemurafenib (0.32 lM) in combination with one of 41 inhibitors
of HDAC, BET, and other chromatin-targeting compounds at three
doses (see Materials and Methods for a list of compounds);
NGFR levels were measured by imaging (Fig 8A). Three BET
bromodomain inhibitors, (+)-JQ1, I-BET, and I-BET151, were
found to consistently suppress NGFR up-regulation when
combined with vemurafenib in technical and biological replicates
(Fig 8A and Appendix Fig S5A). All three compounds also
reduced Ki-67 levels (Appendix Fig S5B) and increased killing of
COLO858 cells when combined with vemurafenib, as measured
by 3-day viability assays and evaluation of drug Emax (Fig 8B;
left panel). For example, when applied to COLO858 cells,
0.32 lM JQ1 slowed down cell division but was not measurably
cytotoxic (Movie EV2) and no more apoptosis was detected than
in a DMSO-only control (Fig EV5). However, a combination of
0.32 lM JQ1 and 1 lM vemurafenib increased apoptosis to
> 90% of cells (1 lM vemurafenib alone induced 40% apoptosis
under these conditions; Fig EV5). Thus, JQ1 and vemurafenib
are synergistic in cell killing by conventional Loewe criteria. JQ1
and the other BET inhibitors were even more effective in
promoting cell killing when vemurafenib and trametinib were
used in combination (Fig 8B; right panel). Moreover, on a plot
of Ki-67 versus NGFR levels, the effects of BET inhibitors (green
arrow) were orthogonal to those of trametinib (red arrow), a
property shared with JNK, FAK, and Src inhibitors (Fig 8C). BET
inhibitors reduced c-Jun up-regulation induced by vemurafenib
to a significant degree (by an average of ~50%; P < 2 × 108)
but did not fully block it (Fig 8D). From these data, we
conclude that chromatin modifications are likely to be involved
in the acquisition of the transiently heritable, NGFRHigh, vemu-
rafenib-resistant cell state and that multiple BET inhibitors can
block this effect.
A
0
500
1000
1500
–
Tr
am
eti
nib
(M
EK
)
De
fac
tin
ib
(F
AK
)
Da
sa
tin
ib
(S
rc)
PF
56
22
71
(F
AK
)
Sa
rac
ati
nib
(S
rc)
N
G
FR
 (a
.u
.)
Effects of co-drugging on NGFR levels
0
200
400
600
800
0
0.5
1
1.5
0 0.32 1
Vemurafenib (μM)
0 0.32 1
N
G
FR
 (a
.u
.)
V
ia
bi
lit
y 
(n
or
m
al
iz
ed
 to
no
n-
ta
rg
et
in
g 
si
R
N
A
) 
NGFR expression Vemurafenib sensitivity
siRNA knockdown in COLO858 cells
P = 2×10–10
Non-targeting JUN PTK2 (FAK) NGFR
siRNA treatments:
JN
K-
IN
-8
(JN
K)
Vemurafenib: 0 μM 0.32 μM 1 μM 
0.01
0.1
1
0.03
0.2
0.5
0.01
0.1
1
0.03
0.2
0.5
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
0
0.3
20.1 1 3.20 0.3
20.1 1 3.2
Vemurafenib Vemurafenib +
Trametinib [10:1] (μM)
Effects of co-drugging on COLO858 viability
JNK-IN-8 (3 μM)
Defactinib (1 μM)
DMSO
Dasatinib (1 μM)
Saracatinib (1 μM)
Additional drug:
B
C D
Effects of co-drugging on COLO858 state
Vem + DMSO
Vem + Trametinib
Vem + Defactinib
Vem + PF562271
Vem + JNK-IN-8
Vem + Dasatinib
Vem + Saracatinib
RAF + MEK
RAF + FAK
RAF + Src
RAF + JNK
Drug combinations Nominal targets
RAF
-1
0
1
2
-1 0 1 2
% Ki-67High (z-score)
N
G
FR
 (l
og
 a
.u
.) 
z-
sc
or
e
Vemurafenib (μM)
RAFi
alone+ MEKi
+ FAKi ,JNKi, Srci
Figure 7. Concurrent inhibition of RAF/MEK signaling and the c-Jun/FAK/Src cascade blocks the NGFRHigh state and increases cell killing.
A NGFR levels as measured by immunofluorescence (left panel) and relative cell viability (right panel) in COLO858 cells following treatment in duplicate with indicated
doses of vemurafenib in the presence of siRNAs targeting JUN, PTK2, and NGFR for 72 h. Viability data for each siRNA condition at each dose of vemurafenib were
normalized to cells treated with the same dose and the non-targeting siRNA.
B NGFR protein levels measured by immunofluorescence in duplicate in COLO858 cells treated for 48 h with indicated doses of vemurafenib, in combination with
DMSO, MEK inhibitor trametinib (0.6 lM), FAK inhibitors defactinib (3 lM) and PF562271 (3 lM), JNK inhibitor JNK-IN-8 (3 lM), or Src inhibitors dasatinib (3 lM) and
saracatinib (3 lM).
C Pairwise comparison between drug combination-induced changes in NGFR and Ki-67 in COLO858 cells treated for 48 h with vemurafenib at 0.32 and 1 lM in
combination with DMSO or two doses of trametinib (0.2, 0.6 lM), defactinib (1, 3 lM), PF562271 (1, 3 lM), dasatinib (1, 3 lM), saracatinib (1, 3 lM), and JNK-IN-8
(1, 3 lM). NGFR and Ki-67 levels were measured by immunofluorescence. For each signal, data were averaged across two replicates, two doses of vemurafenib, and
two doses of the second drug, log-transformed, and z-score-scaled across seven different drug combinations.
D Relative viability of COLO858 cells treated for 72 h with vemurafenib or vemurafenib plus trametinib (10:1 dose ratio) in combination with DMSO, JNK-IN-8,
dasatinib, saracatinib, and defactinib at indicated doses. Viability data were measured in three replicates and normalized to DMSO-treated controls.
Data information: Data in (A, B, D) are presented as mean  SD. Statistical significance was determined by two-way ANOVA.
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Figure 8. BET inhibitors suppress the slowly cycling NGFRHigh state and effectively reduce the cancer cell population with time.
A COLO858 cells were treated for 48 h in duplicate with vemurafenib (at 0.32 lM) in combination with DMSO or three doses (0.11, 0.53, and 2.67 lM) of each of 41
compounds in a chromatin-targeting library. NGFR protein levels were measured by immunofluorescence, averaged across three doses of each compound, and
z-scored.
B Relative viability of COLO858 cells treated for 72 h with vemurafenib or vemurafenib plus trametinib (10:1 dose ratio) in combination with DMSO, (+)-JQ1, I-BET, and
I-BET151 at indicated doses. Viability data were measured in three replicates and normalized to DMSO-treated controls.
C Pairwise comparison between drug-induced changes in NGFR and Ki-67 in COLO858 cells treated with vemurafenib at 0.32, 1, and 3.2 lM in combination with DMSO
or trametinib (0.2 lM), I-BET (1 lM), I-BET151 (1 lM), and (+)-JQ1 (1 lM) for 48 h. Data for each drug combination were averaged across two replicates and three
doses of vemurafenib, log-transformed, and z-score-scaled.
D c-Jun protein levels measured by immunofluorescence in duplicate in COLO858 cells treated for 48 h with indicated doses of vemurafenib, in combination with
DMSO, I-BET (1 lM), (+)-JQ1 (1 lM), and I-BET151 (1 lM).
E Single-cell analysis of division and death events following live-cell imaging of COLO858 cells treated with 1 lM vemurafenib in combination with DMSO or (+)-JQ1
(0.32 lM) for 84 h. Data are presented as described in Figure 1.
F Time-lapse analysis of COLO858 cells treated in three replicates for ~1 week with different drug combinations at indicated doses. Data for DMSO-treated cells are
shown until day 3, the time at which cells reach ~100% confluency.
Data information: Data in (B, D, F) are presented as mean  SD.
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NGFR-suppressing drug combinations block the emergence of
slowly cycling cells and effectively reduce the cancer cell
population with time
To link the activities of drugs that inhibit induction of NGFR by
vemurafenib to the kinetics of cell killing, we performed live-cell
imaging of COLO858 cells in the presence of 1 lM vemurafenib
alone or in combination with 0.32 lM JQ1. Co-drugging eliminated
the emergence of slowly cycling cells (pink) and increased the frac-
tion of cells undergoing apoptosis to > 95% (Fig 8E and
Appendix Fig S5C and D, and Movie EV3). We also monitored cell
growth every 45 min for ~7 days using a live-cell microscope (an
IncuCyte Live Cell Analysis System) that is placed in an incubator
and results in minimal perturbation of growth conditions. In vemu-
rafenib-treated cells (Fig 8F; pink line), both cell division and cell
death were observed between 0 and 30 h after which cell number
was nearly constant. Co-drugging with trametinib increased cell
killing (red), but by the end of one week, the number of viable cells
was still ~50% of the initial number (t = 0). Exposure of cells to JQ1
alone induced cytostasis with little cell killing (light blue), whereas
the combination of vemurafenib plus JQ1 was highly cytotoxic,
resulting in continuous cell killing throughout the 7-day assay
period (blue); the triple combination of vemurafenib, trametinib,
and JQ1 was even more effective (purple). Live-cell analysis of
COLO858 cells exposed to combinations of vemurafenib, trametinib,
and the FAK inhibitor defactinib yielded comparable findings
(Appendix Fig S5C–F). These data show that a drug identified on
the basis of its ability to block acquisition of an NGFRHigh state also
blocks the emergence of slowly growing, vemurafenib-adapted cells
and, as a consequence, causes a sustained increase in the rate of cell
killing.
JNK, FAK, Src, and BET inhibitors overcome the NGFRHigh state in
additional BRAFV600E/D melanoma lines
To investigate the generality of the biology described above, we
analyzed seven additional BRAFV600E/D melanoma cell lines. In two
of these lines (A375 and WM115), NGFR levels were high in the
absence of vemurafenib but increased modestly in a dose-dependent
manner following 48-h exposure to 0.1–1 lM vemurafenib (Fig 9A
and Appendix Fig S6A–C). Concomitantly, these lines exhibited up
to ~sevenfold dose-dependent increase in c-Jun levels (Appendix Fig
S6D). The five other lines we examined exhibited no detectable
increase in NGFR or c-Jun levels upon exposure to vemurafenib.
These findings are consistent with previous data showing that
adaptation to vemurafenib is heterogeneous across cell lines
(Fallahi-Sichani et al, 2015), but overall, a statistically significant
and positive correlation was observed between vemurafenib-induced
c-Jun and NGFR levels (Pearson’s q = 0.86, P = 0.001) (Fig 9B).
When we measured the levels of TSP-1, integrin b1, and
p-FAKY397 in A375 and WM115 cells, we observed vemurafenib-
induced increases in expression and/or high basal levels, in contrast
to low basal levels and an absence of induction in drug-treated
NGFRLow MZ7MEL cells (Appendix Fig S6E and Fig EV3B). In
common with COLO858 cells, co-drugging A375 and WM115 cell
lines with JNK-IN-8, dasatinib, saracatinib, defactinib, and either
vemurafenib or vemurafenib plus trametinib increased cell killing
(and reduced Emax), but co-drugging had no significant effect on
killing of MZ7MEL cells (Fig 9C and Appendix Fig S6F). When we
repeated a focused screen for epigenome-targeting compounds in
A375 and WM115 cells, we identified the same three BET inhibitors
JQ1, I-BET, and I-BET151 as capable of blocking vemurafenib-
induced NGFR up-regulation (Appendix Fig S7A–C). All three of
these compounds enhanced cell killing when combined with
vemurafenib or vemurafenib plus trametinib (Fig 9D). On a plot of
NGFR versus Ki-67 levels, the effects of co-drugging A375 or
WM115 cells with vemurafenib and inhibitors of BET proteins, JNK,
FAK, or Src were orthogonal to those of co-drugging with
trametinib, in all cases reducing the fraction of Ki-67High and
NGFRHigh cells relative to vemurafenib alone but without further
reducing p-ERK levels (Fig 9E and F, and Appendix Fig S7D and E).
From these data, we conclude that even though basal NGFR levels
vary significantly among COLO858, A375, and WM115 cells, all
three lines exhibit similar drug adaptation in the presence of MAPK
inhibitors.
The NGFRHigh state is associated with resistance to MAPK
inhibitors in some melanoma patients
When tumor biopsies from drug-naı¨ve melanoma patients were
immunostained for NGFR, we observed variability from one tumor
to the next and, within a single tumor, from one region to the next:
NGFRHigh/MITFLow and NGFRLow/MITFHigh domains were present
in 4/11 samples and the former stained less strongly for Ki-67
(Fig 10A and Appendix Fig S8). We obtained biopsies from a patient
prior to the onset of therapy, 2 weeks after initiation of therapy with
dabrafenib plus trametinib and subsequent to relapse and then
measured NGFR, Ki-67, and c-Jun levels by immunostaining. Rela-
tive to the pre-treatment biopsy, the on-treatment biopsy exhibited a
reduction in the fraction of Ki-67High cells from ~23% to ~4%,
Figure 9. JNK, FAK, Src, and BET inhibitors overcome the NGFRHigh drug-resistant state in additional BRAFV600E/D melanoma lines.
A NGFR protein levels measured in duplicate by immunofluorescence in seven BRAFV600E/D cell lines treated with vemurafenib at indicated doses for 48 h.
B Correlation between vemurafenib-induced changes in c-Jun and NGFR protein levels across nine BRAFV600E/D melanoma cell lines. Cells were treated with five doses
of vemurafenib (0, 0.1, 0.32, 1, and 3.2 lM) for 48 h. c-Jun and NGFR protein levels measured by immunofluorescence at each condition were averaged across two
replicates and normalized to DMSO-treated controls. The area under the dose–response curve (AUC) for the two measurements (c-Jun and NGFR) was calculated,
z-score-scaled across nine cell lines, and their pairwise Pearson’s correlation was reported.
C, D Relative viability of A375 and WM115 cells treated in 3 replicates for 72 h with vemurafenib or vemurafenib plus trametinib (10:1 dose ratio) in combination with
indicated kinase inhibitors (C) or BET inhibitors (D).
E, F Pairwise comparison between NGFR and Ki-67 levels in A375 and WM115 cells treated with vemurafenib in combination with indicated kinase inhibitors (E) or BET
inhibitors (F). Drug doses, time points, and data normalization are similar to Figs 7C and 8C.
Data information: Data in (A, C, D) are presented as mean  SD.
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consistent with the anticipated effects of dabrafenib/trametinib ther-
apy, but the fraction of NGFRHigh cells increased from ~7% to ~30%
(Fig 10B). The distribution of signal intensities across single cells
suggested that these changes primarily involved a switch from a
Ki-67High/NGFRLow state to a Ki-67Low/NGFRHigh state following
initiation of therapy. This change was associated with an increase in
c-Jun expression (Fig 10C; compare yellow and black distributions).
Following relapse, the fraction of Ki-67High cells increased dramati-
cally (to ~74%) reflecting re-acquisition of proliferative potential
and ~20% of these cells were NGFRHigh. Relapse was also accompa-
nied by a dramatic increase in c-Jun levels (Fig 10C; red distribu-
tion). Although the number of samples in this study is low, the data
are consistent with a heterogeneous distribution of NGFRHigh/
Ki-67Low and NGFRLow/Ki-67High domains in melanoma tumors, and
a drug-mediated induction of NGFRHigh/Ki-67Low state that is
concomitant with c-Jun up-regulation, a situation reminiscent of our
observations in cultured cells.
To investigate changes in NGFR levels across a larger cohort of
BRAF-mutant melanoma patients, we analyzed two published
RNA-seq datasets involving matched samples from 21 tumors
pre-treatment and following emergence of resistance to different
combinations of RAF/MEK inhibitors (Sun et al, 2014; Hugo et al,
2015). In 62% of biopsies from patients with acquired drug resis-
tance, NGFR gene expression increased as compared to pre-treat-
ment levels (Fig 10D). MITF expression fell in only 50% of these
biopsies, suggesting that therapy-induced NGFR up-regulation and
MITF down-regulation do not necessarily occur concomitantly.
GSEA of these tumors identified ECM–receptor interactions and
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Figure 10. The NGFRHigh state is associated with resistance to MAPK inhibitors in a subset of melanoma patients.
A Immunohistochemical analysis of vemurafenib-naïve tumors from three melanoma patients stained for NGFR, MITF, and Ki-67 (see Materials and Methods for
patient clinical information).
B Covariate single-cell analysis of Ki-67 versus NGFR measured by immunofluorescence in pre-treatment, on-treatment (with dabrafenib and trametinib combination
for 2 weeks), and post-relapse tumor biopsies of a BRAF-mutant melanoma patient (see Materials and Methods for patient clinical information).
C Cell population histograms representing c-Jun variations measured by immunofluorescence in the same patient-matched biopsies as shown in (B).
D NGFR gene expression changes in 21 matched pairs of pre-treatment and post-resistance tumor biopsies analyzed by RNA sequencing. MITF changes are shown for
tumors with a post-resistance NGFR increase (increase = log2 (fold-change) > 0.5, decrease = log2 (fold-change) < 0.5, no change = |log2 (fold-change)| ≤ 0.5).
Gene expression data from patients treated with RAF inhibitor, MEK inhibitor, or their combination were analyzed by combining two published datasets (Sun et al,
2014; Hugo et al, 2015).
E Ranked GSEA plots of top KEGG pathways significantly correlated with NGFR expression in 18 matched pairs of pre-treatment and post-resistance tumor biopsies
(Hugo et al, 2015).
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focal adhesion among the top enriched KEGG pathways correlated
with NGFR gene expression levels, consistent with data obtained in
cell lines (Fig 10E, and Datasets EV3 and EV4). We conclude that
melanomas exhibit variability in differentiation status pre- and
post-treatment but that acquisition of an NGFRHigh state is associ-
ated with resistance to RAF/MEK-targeted therapy in about half of
melanomas examined.
JQ1 suppresses induction of an NGFRHigh state in BRAFV600E
melanoma xenografts
To test whether the NGFRHigh phenotype can be blocked in vivo
by drugs identified as effective in cell lines, we analyzed A375
cells grown as xenografts in nude mice. A375 cells are among the
most widely used xenograft models for BRAF-mutant melanoma.
Mice were exposed for 5 days to RAF inhibitor dabrafenib (at a
25 mg/kg dose) alone or in combination with JQ1 (at a 50 mg/kg
dose). Four xenograft tumors per condition were excised, fixed,
sectioned, and then co-stained for NGFR and Ki-67. Analysis of
staining intensity at a single-cell level revealed heterogeneity from
one region of tumor to the next and a reciprocal relationship
between regions of the tumor that were NGFRHigh and Ki-67High
(Fig 11A), a pattern similar to what was observed in human
tumors. Treatment of animals with dabrafenib plus JQ1 signifi-
cantly reduced the fraction of NGFRHigh cells as compared to
dabrafenib alone (or vehicle-treated controls) and the combination
also reduced the fraction of Ki-67High cells relative to dabrafenib or
vehicle (Fig 11B). These data mimic two key aspects of what we
observed in cultured A375 cells (which have high NGFR levels in
the basal state): First, JQ1 can reduce NGFR levels, and second,
JQ1 and dabrafenib can combine to reduce the fraction of prolifer-
ating Ki-67High cells. Moreover, as these experiments were being
conducted, a study was published on tumor burden in mice
engrafted with A375 tumors. It showed that JQ1 and vemurafenib
have synergistic effects of tumor shrinkage (Paoluzzi et al, 2016).
Together, these findings establish that the effects of co-drugging
with JQ1 and MAPK inhibitors observed in cell culture can also be
obtained in xenograft models. This sets the stage for large-scale
pre-clinical evaluation of drugs such as BET bromodomain
inhibitors as a means of blocking drug adaptation and increasing
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Figure 11. The NGFRHigh phenotype can be suppressed by JQ1 in BRAFV600E melanoma xenografts.
A Immunofluorescence analysis of A375 melanoma xenograft tumors co-stained for Ki-67 and NGFR proteins. Selected images from a whole tumor section as well as
NGFRHigh/Ki-67Low and NGFRLow/Ki-67High regions of a vehicle-treated tumor are shown to highlight the spatial and cell-to-cell heterogeneity in Ki-67 and NGFR
protein expression.
B Percentage of Ki-67High and NGFRHigh cells in tumors treated for 5 days with dabrafenib (25 mg/kg) only, dabrafenib (25 mg/kg) in combination with JQ1 (50 mg/kg),
or vehicle. Number of tumors (mice) analyzed per condition is shown. Solid horizontal lines represent the mean of measurements. Up to 50,000 individual cells per
tumor were analyzed for NGFR and Ki-67 intensities. Statistical significance was determined using two-tailed two-sample t-test.
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cell killing by MAPK inhibitors in a subset of BRAF-mutant
melanomas.
Discussion
In this paper, we use time-lapse, live-cell imaging, and single-cell
analysis to show that BRAF-mutant melanoma cells exhibit time-
variable and heterogeneous phenotypes when exposed to MAPK
pathway inhibitors such as vemurafenib, dabrafenib, and trametinib
near the IC50 for cell killing. Cells initially undergo growth arrest,
consistent with the known requirement for MAPK activity in prolif-
eration. Apoptosis peaks between 48 and 72 h and typically kills
40–60% of cells, while other cells enter a G0/G1 arrest. In a subset
of lines, a subpopulation of cells overcomes drug-mediated cell cycle
arrest and begins to divide threefold to fourfold more slowly than
drug-naı¨ve cells. Such adapted cells exhibit elevated neural crest
markers including NGFR and neurogenesis genes, suggestive of
drug-induced de-differentiation and consistent with previous studies
associating increased NGFR levels or loss of melanocyte differentia-
tion markers (e.g., MITF) with resistance to MAPK pathway
inhibitors (Konieczkowski et al, 2014; Muller et al, 2014; Ravindran
Menon et al, 2015). In culture, the generation of slowly cycling
NGFRHigh cells reduces drug maximal effect, as evidenced by
short-term (3-day) viability assays and week-long time-lapse
imaging. Slowly cycling, drug-adapted cells are likely to contribute
to residual disease and eventual emergence of genetically distinct
drug-resistant clones (Frick et al, 2015; Hata et al, 2016).
Reversible drug resistance
The slowly cycling NFGRHigh state induced by vemurafenib is only
transiently stable: After 9 days of outgrowth in drug-free medium,
such cells reset to their initial state as measured by restoration of
vemurafenib sensitivity, increased proliferation rate, and reduced
expression of NGFR. Such metastable, bidirectional changes in cell
state are inconsistent with selection of pre-existing genetic variants
but are more durable than transiently heritable differences gener-
ated by stochastic fluctuation in protein levels (Cohen et al, 2008;
Gascoigne & Taylor, 2008; Flusberg et al, 2013). Instead, the
phenomenon is reminiscent of drug-tolerant persisters (DTPs),
which constitute < 1% of drug-naı¨ve cell populations, become
enriched following exposure to high concentrations of anti-cancer
drugs (> 100-fold above IC50 values) for > 9 days, and have
hyperactive IGF-1R signaling (Sharma et al, 2010). Like NGFRHigh
melanoma cells, DTPs are sensitive to some kinase inhibitors and to
inhibitors of epigenome-modifying enzymes, HDACs in the case of
DTPs, and BET inhibitors in the case of vemurafenib-adapted
melanoma cells. However, time-lapse imaging shows that melanoma
cells responding to vemurafenib induce a slowly dividing drug-
adapted state more rapidly and in a larger fraction of cells (> 20% of
cells by 3 days near the vemurafenib IC50) than has been observed
for DTPs. We speculate that differences between these phenomena
originate primarily from differences in the strength and timing of
imposed selective pressures; whereas acutely high doses of drug lead
to selection of a small percentage of intrinsically, highly insensitive
cells (i.e., DTPs) (Sharma et al, 2010; Roesch et al, 2013), lower and
more realistic drug doses provide a larger fraction of cells with
sufficient time to induce an adaptive mechanism and become drug
insensitive; once induced, this resistance appears to protect cells
from higher doses of drug (Ravindran Menon et al, 2015).
Our data add to a growing body of research suggesting that
tumor cells can reversibly undergo dynamic changes that create
subpopulations of cells with different proliferative potentials and
sensitivity to apoptosis. Stochastic fluctuation in protein levels
(Spencer et al, 2009), DTPs, and NGFRHigh melanoma cells repre-
sent three distinguishable but related mechanisms of achieving a
state of reversible drug resistance. Such cells are thought to be the
basis of residual disease and to provide a pool for further genetic or
epigenetic changes that eventually induce the growth of drug-
resistant clones (Hata et al, 2016).
A speculative pathway for reversible drug resistance
in melanoma
Based on data from drug-adapted cells in culture, the efficacy of
co-drugging these cells with kinase and BET bromodomain inhibi-
tors and analysis of gene expression profiles in human melanoma
biopsies, we propose a speculative model for the adaptive resistance
to RAF/MEK inhibition characterized in this paper. Exposure of
BRAF-mutant melanoma cells to MAPK inhibitors initially induces
up-regulation of JNK/c-Jun signaling, a known regulator of
EMT-related genes and of cell adhesion and ECM molecules (Liu
et al, 2015; Ramsdale et al, 2015). Up-regulation of cell adhesion
proteins is accompanied by activation of FAK and downstream Src
kinases, causing cells to acquire a distinct epigenetic state and
become more neural crest-like. Such cells divide slowly and have a
reduced requirement for ERK signaling.
We and others have recently reported that JNK and c-Jun are acti-
vated in a subset of melanomas exposed to MAPK inhibitors (Delmas
et al, 2015; Fallahi-Sichani et al, 2015; Ramsdale et al, 2015; Riesen-
berg et al, 2015; Titz et al, 2016). Our current study links this
phenomenon to transiently heritable (reversible) de-differentiation by
a subset of cells in the population and to high expression of NGFR,
which has previously been observed in human tumors. We also iden-
tify compounds other than JNK inhibitors able to block drug adapta-
tion and increase cell killing. Studies on an as-yet limited number of
biopsies show that NGFR expression is induced by MAPK inhibitors in
human tumors, concomitant with a reduction in cell proliferation; this
effect is highly heterogeneous across a single human tumor and also
across a xenograft, the former representing a genetically heteroge-
neous sample and the latter a more homogenous one. In a human
tumor analyzed prior to therapy, on therapy and following progres-
sion, we find that c-Jun levels increase upon initial MAPK inhibition
and rise further when tumors become drug-resistant. Thus, it seems
plausible that mechanisms identified in cultured cells are also opera-
tive in real tumors. It is important to note, however, that JNK/c-Jun-
dependent adaptation marked by an NGFRHigh state, as described here,
appears to occur in only a subset (about one-third) of cell lines stud-
ied. Other mechanisms are presumably operative in other cell lines.
Inhibitors of adaptive drug resistance
By targeted screening, we identify two classes of compounds with
the potential to block vemurafenib-induced de-differentiation (as
marked by elevated NGFR expression): (i) small-molecule kinase
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inhibitors against components of the postulated c-Jun/FAK/Src
cascade and (ii) epigenetic modifiers, including BET bromodomain
inhibitors presumed to block the de-differentiation program.
Combining vemurafenib with JNK, FAK, or Src kinase inhibitors, or
with BET inhibitors suppresses acquisition of the NGFRHigh
phenotype, prevents the emergence of slowly cycling drug-resistant
cells, and enhances cell killing. In the case of BET inhibitor JQ1, we
also show that co-drugging suppresses the NGFRHigh state in
BRAF-mutant melanoma xenografts treated with dabrafenib. The
primary effect of co-drugging on cultured cells is on maximum effect
(Emax) and involves reducing viable cell number (in a 3-day assay)
from 1% to 10% of the initial population to 0.01–0.1%. In our opin-
ion, such an effect would be missed by most protocols used to
screen for drug combinations.
The molecular effects of RAF/MEK and JNK/FAK/Src/BET
inhibitors appear to be orthogonal, with the former suppressing
MAPK signaling and the latter suppressing the consequent emer-
gence of de-differentiated, adapted cells. Moreover, experiments
with vemurafenib and trametinib show that the greater the extent of
MAPK inhibition, the greater the extent of adaptation. Thus, inhibi-
tors of adaptation such as dasatinib (Sprycel) might be expected to
combine with MAPK inhibition in therapeutically beneficial ways.
Inhibiting Src family kinases has previously been reported to over-
come resistance to RAF inhibitors (Girotti et al, 2013), although this
was attributed to a role for Src downstream of RTKs rather than
FAK. Vemurafenib has also been shown to activate melanoma-
associated stromal fibroblasts, increasing ECM production and
elevating integrin/FAK/Src signaling to promote vemurafenib resis-
tance in nearby melanoma cells (Hirata et al, 2015). All three of
these mechanisms could be involved at the same time, perhaps to
different extents in different settings.
Current understanding of biomarkers for vemurafenib-induced
de-differentiation in melanomas remains incomplete. For example,
the switch of melanoma cells in culture to a drug-resistant NGFRHigh
phenotype is not associated with a reduction in MITF levels. More-
over, only about half of NGFRHigh post-resistance biopsies exhibited
a reduction in MITF levels, suggesting that therapy-induced NGFR
up-regulation and MITF down-regulation are not necessarily
concomitant. Low MITF expression in melanomas has previously
been linked to increased expression of RTKs such as AXL, EGFR,
and PDGFRb, which activate immediate–early signaling, causing
resistance to RAF/MEK inhibitors (Muller et al, 2014). However, the
NGFRHigh phenotype we observe is not associated with RTK
up-regulation as judged by mRNA expression. These findings raise
the question whether we and others are probing different aspects of
a unified adaptive mechanism common to all melanomas or
whether adaptation is fundamentally different in genetically distinct
tumor cells. Answering this question at a single-cell level may help
identify novel therapies and biomarkers that have been missed by
experiments that focus on bulk tumor cell killing.
Materials and Methods
Cell culture
Melanoma cell lines used in this study were obtained from the
Massachusetts General Hospital Cancer Center with the following
primary sources: COLO858 (ECACC), A375, C32, WM115,
SKMEL28, and WM1552C (ATCC), LOXIMV1 (DCTD Tumor Reposi-
tory, National Cancer Institute), MMACSF (RIKEN BioResource
Center), and MZ7MEL (Johannes Gutenberg University Mainz).
C32, MMACSF, SKMEL28, and WM115 cell lines were grown in
DMEM/F12 (Invitrogen) supplemented with 5% fetal bovine serum
(FBS) and 1% sodium pyruvate (Invitrogen). COLO858, LOXIMVI,
MZ7MEL, and WM1552C cell lines were grown in RMPI 1640 (Corn-
ing cellgro) supplemented with 5% FBS and 1% sodium pyruvate
(Invitrogen). A375 cells were grown in DMEM with 4.5 g/l glucose,
L-glutamine, and sodium pyruvate (Corning cellgro), supplemented
with 5% FBS. We added penicillin (50 U/ml) and streptomycin
(50 lg/ml) to all growth media.
Reagents and antibodies
Chemical inhibitors from the following sources were dissolved in
dimethyl sulfoxide (DMSO) as 10 mM stock solution and used in
treatments: vemurafenib (MedChem Express), trametinib
(GSK1120212), defactinib, PF562271, pictilisib (GDC0941), palboci-
clib (PD0332991), and AZD8055 (all from Selleck Chemicals),
JNK-IN-8 (EMD Millipore), dasatinib, saracatinib, (+)-JQ1, I-BET,
I-BET151, and belinostat (all from Haoyuan Chemexpress). The
following primary antibodies with specified animal sources and
catalogue numbers were used in specified dilution ratios in
immunofluorescence analysis of cells and tissues: p-S6S240/244 rabbit
monoclonal antibody (mAb) (clone D68F8, Cat# 5364), 1:800;
p-ERKT202/Y204 rabbit mAb (clone D13.14.4E, Cat# 4370), 1:800;
c-Jun rabbit mAb (clone 60A8, Cat# 9165), 1:800; p-c-JunS73 rabbit
mAb (clone D47G9, Cat# 3270), 1:800; Ki-67 mouse mAb (clone
8D5, Cat# 9449), 1:400; c-Jun mouse mAb (clone L70B11, Cat#
2315), 1:200; p75NTR (NGFR) rabbit mAb (clone D4B3, Cat# 8238),
1:1,600 (for staining cultured cells) or 1:200 (for staining tissue
sections); all from Cell Signaling Technology, and p-RbS807/811 goat
polyclonal antibody (Cat# sc-16670), 1:400, from Santa Cruz Biotech-
nology. The following antibodies were diluted 1:1,000 and used in
Western blots: p-FAKY397 rabbit mAb (clone D20B1, Cat# 8556), FAK
rabbit mAb (clone D2R2E, Cat# 13009), integrin b1 rabbit mAb
(clone D2E5, Cat# 9699), p75NTR (NGFR) rabbit mAb (clone D4B3,
Cat# 8238), b-actin rabbit mAb (clone D6A8, Cat# 8457), all from
Cell Signaling Technology; HSP90a/b rabbit polyclonal antibody
(Cat# sc-7947) from Santa Cruz Biotechnology; and thrombospondin
rabbit polyclonal antibody (Cat# ab85762) from Abcam.
Human tumor specimens
Under IRB-approved protocols, freshly procured and discarded
melanoma tumor specimens were formalin-fixed, paraffin-
embedded, sectioned, and stained with H&E for histopathological
evaluation or immunofluorescence staining. Clinical history of the
drug-naive patients (age, sex, BRAF mutation, sequencing method,
treatment history) is as follows: patient 1 (74, male, wild-type,
whole-exome sequencing, no prior treatment), patient 2 (58, male,
BRAFV600E, targeted sequencing, no prior treatment), patient 3 (86,
female, BRAFV600E, whole-exome sequencing, no prior treatment),
and patient 4 (65, male, BRAFV600E, targeted sequencing, interferon).
In the case of patient-matched biopsies from pre-treatment, on-
treatment (for 2 weeks), and post-relapse tumors, biopsies were
ª 2017 The Authors Molecular Systems Biology 13: 905 | 2017
Mohammad Fallahi-Sichani et al Overcoming adaptive resistance to RAF inhibition Molecular Systems Biology
17
collected from a male patient with metastatic BRAF-mutant
melanoma, treated with dabrafenib and trametinib combination.
Immunohistochemistry of human tumor specimens
Tumor sections were deparaffinized, and heat-induced epitope
retrieval (HIER) was performed on the unit using EDTA for 20 min
at 90°C. Sections were incubated for 30 min with primary antibodies
including Ki-67 rabbit monoclonal antibody (clone SP6, Cat#
VP-RM04) from Vector Laboratories, p75NTR/NGFR rabbit poly-
clonal antibody (Cat# 119-11668) from RayBiotech, and MITF
mouse monoclonal antibody (clone D5, Cat# MA5-14154) from
Thermo Scientific, and were then completed with the Leica Refine
detection kit (secondary antibody, the DAB chromogen, and the
hematoxylin counterstain).
Live-cell reporter constructs
To generate cells expressing fluorescently tagged geminin and H2B,
we used the pPB-CAG.EBNXN/pCMV-hyPBase transposase vector
system (Allan Bradley, Sanger Institute). First, a pPB-CAG vector
containing a multiple cloning site (pPB-CAG-MCS) was generated by
annealed oligo cloning of the following primers into the EcoRI and
SalI restriction sites of pPB-CAG-EKAREV (Albeck et al, 2013)
containing a puromycin selection cassette: 50-aattcggatcccatatgca
cgtgctcgagg-30 and 50-tcgacctcgagcacgtgcatatgggatccg-30. Next, inter-
mediate pPB-CAG constructs were generated for ERK-KTR-mTur-
quoise2, H2B-Venus, and mCherry-geminin performing Gibson
Assembly (New England Biolabs) at the EcoRI and SalI restriction
sites and using the following templates and primers: ERK-KTR
(Regot et al, 2014) with 50-tctcatcattttggcaaagaattcggcatgaagggccga
aagcct-30 and 50-ctcaccatactagtggatgggaattgaaag-30 and mTurquoise2
(Goedhart et al, 2012) with 50-ccactagtatggtgagcaagggcgag-30 and 50-ca
cacattccacagggtcgacttacttgtacagctcgtccatg-30; H2B (Nam & Benezra,
2009) with 50-tctcatcattttggcaaagaattcggcatgcctgaaccctctaagtctgc-30
and 50-ctcaccatggtggcgaccggtggatc-30 and Venus with 50-tcgccaccatgg
tgagcaagggcgag-30 and 50-cacacattccacagggtcgacttatttgtacaattcgtccatc
ccc-30; mCherry with 50-tctcatcattttggcaaagaattcggcatggtgagcaag
ggcgag-30 and 50-ggatatcccttgtacagctcgtccatgc-30 and geminin
(Sakaue-Sawano et al, 2008) with 50-ctgtacaagggatatccatcacactggc-30
and 50-cacacattccacagggtcgacttacagcgcctttctccg-30. These intermedi-
ate constructs were used as templates for a final round of Gibson
cloning to generate pPB-CAG-ERK-KTR-mTurquoise2-P2A-H2B-
Venus-P2A-mCherry-geminin in which the DNA coding for three
live-cell reporters is separated by self-cleaving P2A sites: ERK-KTR-
mTurquoise2 with 50 ctgtctcatcattttggcaaag-30 and 50-cacgtcgcca
gcctgcttaagcaggctgaagttagtagctccgcttcccttgtacagctcgtccatg-30, H2B-
Venus with 50-ttcagcctgcttaagcaggctggcgacgtggaggagaaccccgggccta
tgcctgaaccctctaag-30 and 50-gacatcccccgcttgtttcaataacgaaaaattcgtcg
cgcccgagcctttgtacaattcgtccatcc-30, mCherry-geminin with 50-ttttcgtt
attgaaacaagcgggggatgtcgaagaaaatccgggcccgatggtgagcaagggcg-30 and
50-ctgacacacattccacagggtcgacttacagcgcctttctccgtttttc-30. Plasmid DNA
was provided by Marcus Covert (ERK-KTR), Joachim Goedhart
(mTurquoise2), Robert Benezra (H2B-mCherry, Addgene plasmid #
20972), Atsushi Miyawaki (geminin), and Allan Bradley (pPB-
CAG.EBNXN and pCMV-hyPBase). Positive clones were confirmed
by sequencing. To create stable cell lines, cells were co-transfected
with the pPB-CAG triple reporter plasmid and pCMV-hyPBase using
FuGene HD (Promega) and transiently selected with puromycin. To
enrich for cells stably expressing the live-cell reporter at comparable
levels, cells were subjected twice to FACS. Reporter and parental
cell lines were confirmed to grow at comparable rates for different
vemurafenib concentrations over 72 h of treatment.
Live single-cell imaging and analysis
Cell lines stably expressing the live-cell reporter were seeded into
Costar 96-well black clear-bottom tissue culture plates (Corning
3603) in 200 ll full growth medium without phenol red at a density
of 4,500 cells per well for COLO858 or 4,000 cells per well for
MMACSF; cells were counted using a Cellometer Auto T4 Cell
Viability Counter (Nexcelom Bioscience). To facilitate cell tracking,
COLO858 reporter cells treated with DMSO were mixed with an
equal amount of parental cells, maintaining an overall cell density
of 4,500 cells/well. The next day, cells were treated with DMSO or
1 lM vemurafenib, or with 1 lM vemurafenib in combination with
DMSO, 3 lM defactinib, 1 lM dasatinib, or 0.32 or 1 lM (+)-JQ1
using an Hewlett-Packard (HP) D300 Digital Dispenser. Within 45–
80 min after drug treatment, image acquisition was started using a
Nikon Ti motorized inverted microscope with a 10× Plan Fluor 0.30
NA Ph1 objective lens and the Perfect Focus System for continuous
maintenance of focus. Plates were placed into an OkoLab cage
microscope incubator set to 37°C, 5% CO2, and 90% humidity to
enable stable environmental conditions throughout the experiment.
Images were acquired every 6 min for the indicated times with a
Hamamatsu ORCA ER cooled CCD camera controlled with Meta-
Morph 7 software, using a 2 × 2 binning. For illumination, the
Lumencor Spectra-X light engine in combination with a CFP/YFP/
mCherry beam splitter (Chroma ID No. 032357) was used. H2B-
Venus fluorescence was collected with a 508/24 excitation and a
540/21 emission filter at 200 ms exposure, and mCherry-geminin
fluorescence was collected with a 575/22 excitation and a 632/60
emission filter at 400 ms exposure.
Individual cells from up to 10 wells per condition were
analyzed. Cell positions and cell death/division events were manu-
ally tracked using a custom MATLAB-based script provided by Jose
Reyes, Kyle W. Karhohs, and Galit Lahav (Harvard Medical
School). Using H2B, a total of 150–217 cells were manually tracked
and cell division and death events were recorded. To derive statisti-
cal mean and variance, cells from multiple wells were pooled
together to generate three or four groups of wells containing ~50–
70 cells. Data from 3 to 4 groups of cells were then used to report
the mean  SD. For extracting the geminin signal, the mean inten-
sity of the centroid dilated by 12 pixels was calculated after using a
rolling ball background subtraction. To determine the onset of S/
G2, a moving average with a window of 40 frames was calculated
for the geminin signal and in general an average value above a
threshold of 2.0 (COLO858) or 1.5 (MMACSF) was determined as
the start of the S/G2 cell cycle stage.
To measure cell division times following longer periods of
vemurafenib treatment (i.e., ~8 days), COLO858 cells were initially
exposed to 1 lM vemurafenib for 2 days, medium was then
changed (to remove apoptotic cells), and cells were treated with
1 lM vemurafenib for an additional 2 days before they were
imaged for ~4 days. Minimum doubling times were estimated for
100 individual cells tracked between days 4 and 8 post-treatment
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by identifying the longest time interval before or after which a cell
divides.
Long-term time-lapse live-cell analysis using IncuCyte
COLO858 cells expressing H2B-mVenus were imaged every 45 min
for ~1 week after treatment in three replicates with indicated drugs
at indicated concentrations with a 4× objective using IncuCyte
ZOOM live-cell imager (Essen Bioscience). Dead cells were identi-
fied by staining with IncuCyte CytoTox Red Reagent (Essen
Bioscience, Cat# 4632). Time-lapse live-cell analysis (following
exclusion of dead cells) was performed using ImageJ software.
Apoptosis, cell viability, and growth rate inhibition assays
For 72–96 h viability, apoptosis, or growth rate inhibition assays,
cells were seeded in 3–6 replicates at 2,500–5,000 cells per well in
96-well plates (Corning 3603) in 180 ll of full growth media; cells
were counted using a Cellometer Auto T4 Cell Viability Counter
(Nexcelom Bioscience). Cells were treated the next day using a
Hewlett-Packard (HP) D300 Digital Dispenser with compounds at
reported doses. To score viability and apoptosis, we used a dye-
based imaging assay: The cell-permeable DNA dye Hoechst 33342
was used to mark nuclei, and DEVD-NucView488 caspase-3
substrate was used to mark apoptosis, as previously described in
detail (Fallahi-Sichani et al, 2015). Imaging was performed using a
10× objective using a PerkinElmer Operetta High Content Imaging
System. Eleven sites were imaged in each well. Image segmentation
and analysis were performed using Acapella software
(PerkinElmer). The nuclear segmentation with Hoechst 33342 was
used to identify individual nuclei and to count cells. To score
apoptotic cells, bright spots were detected by dividing NucView488
channel nuclear intensity by the nucleus area and spots brighter
than a separating threshold were scored as apoptotic. Relative
viability was calculated by subtracting the number of apoptotic cells
from the total number of cells to achieve viable cell count at each
condition that was normalized to a DMSO-treated control. To
compare drug effect on different cell populations that grow at dif-
ferent rates (e.g., FACS-sorted NGFRHigh and NGFRLow cells), growth
rate (GR) inhibition was calculated by normalizing viable cell count
data to the growth rate of untreated cells as described previously
(Hafner et al, 2016). Data were analyzed using MATLAB 2014b
software.
RNA extraction, library construction, and RNA-seq analysis
COLO858 and MMACSF cells were seeded in 10-cm plates in two
replicates, treated the next day with either DMSO or 0.2 lM vemu-
rafenib for 24 and 48 h. At the time of harvest for RNA, cells were
washed once with PBS and then lysed in the dish with RLT buffer
(Qiagen). Samples were immediately processed with Qiashredder
and RNeasy kits (Qiagen) and frozen until further use. 10 lg of
RNA was DNAse-treated and cleaned up with RNeasy MinElute kit
(Qiagen). RNA quality was assessed by Bioanalyzer (Agilent), and
all samples had RINs of 9.0 or higher. RNA-seq libraries were
constructed using Illumina’s TruSeq-stranded mRNA library prep kit
and protocol with minor modifications. Briefly, 1 lg of RNA was
mixed with 2 ll of a 1:100 dilution of ERCC spike in control Mix2
(Life Technologies) before mRNA purification. Elution and
fragmentation was done for 6 min at 94°C. cDNA was synthesized
and cleaned up with Ampure beads (Agencourt). Fragments were
end-modified and adaptors ligated before another Ampure bead
cleanup. Final library amplification was done at 13 cycles and again
cleaned up with Ampure beads. The resulting libraries were roughly
380 bp in length as assessed by Bioanalyzer. RAN-seq was
performed at the Harvard University Sequencing Facility (FAS Divi-
sion of Science) on Illumina HiSeq 2000 machines using the stan-
dard single-read (1 × 50 bp) protocol. The reads were mapped to
the human genome (build hg19) using Tophat (Kim et al, 2013)
with default settings, and differential expression analysis was
performed using Cuffdiff (Trapnell et al, 2010) running on the
web-based Galaxy platform (https://usegalaxy.org/). To identify dif-
ferentially regulated genes between COLO858 and MMACSF cells,
we first selected genes whose expression at 24 or 48 h following
treatment changed relative to a DMSO-treated control (q < 0.01) in
at least one of the cell lines; we then identified those genes with
FPKM ≥ 1, that changed in abundance by more than twofold
between the two cell lines (|log2 (ratio)| ≥ 1), where “ratio” repre-
sents treatment versus DMSO fold-change in COLO858 divided by
the treatment versus DMSO fold-change in MMACSF cells. Differen-
tially regulated genes were processed using Metacore (Genego, Inc)
software available online (http://portal.genego.com/). Ranked
biological processes and pathways were generated using “analyze
single experiment” feature with default settings.
Hierarchical clustering
Unsupervised hierarchical clustering of expression levels of differen-
tially regulated genes between COLO858 and MMACSF cell lines
was carried out using MATLAB 2014b, using the Chebyshev
distance as the metric. (FPKM + 1) values of vemurafenib-treated
conditions were normalized to those of DMSO-treated controls and
log2-transformed prior to clustering.
Bioinformatics analysis
Gene expression data analysis and heat-map visualization were
performed using MATLAB 2014b software. Differentially expressed
genes with transcription factor activity and genes associated with
cell surface receptors and secreted peptides/proteins were identified
using Advanced Search 2.0 feature of the online Genego database
(https://portal.genego.com/). Enriched transcriptional regulators
for the list of differentially expressed genes were predicted using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 (http://david.ncifcrf.gov/) (Huang da et al, 2009a,b),
and they were compared to the gene expression levels of transcrip-
tion factors 24–48 h after vemurafenib treatment.
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) (Mootha et al, 2003; Subrama-
nian et al, 2005) was performed using GSEA v2.2.0 software with
1,000 phenotype permutations. Gene Ontology (GO) biological
processes (c5.bp.v5.0.symbols.gmt), and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway (c2.cp.kegg.v5.0.sym-
bols.gmt) gene sets were obtained from http://www.broadinstitute.
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org/gsea/downloads.jsp and used in GSEA. To identify biological
processes and pathways most correlated with NGFR expression, we
performed GSEA on RNA-seq data of tumors from 128 BRAFV600E
melanoma patients included in TCGA (Cancer Genome Atlas
Network, 2015), and microarray data of 25 BRAFV600E melanoma
cell lines in the CCLE (Barretina et al, 2012), and by selecting NGFR
expression levels as the “phenotype” and “Pearson” as the metric
for ranking genes. A detailed description of GSEA methodology and
interpretation is provided at http://www.broadinstitute.org/gsea/d
oc/GSEAUserGuideFrame.html. Briefly, enrichment score indicates
“the degree to which a gene set is overrepresented at the top or
bottom of a ranked list of genes”. The false discovery rate (FDR
q-value) is “the estimated probability that a gene set with a given
enrichment score represents a false positive finding”. “In general,
given the lack of coherence in most expression datasets and the rela-
tively small number of gene sets being analyzed, an FDR cutoff of
25% is appropriate”.
Fluorescence-activated cell sorting
COLO858 cells were seeded in 15-cm plates, treated the next day
with 0.32 lM vemurafenib for 48 h. The cell monolayer was incu-
bated at 37°C with trypsin 0.05% (Gibco) for 1 min, lifted from the
plate with a cell scraper and re-suspended in PBS with 2% FBS. The
cell suspension was washed in PBS with 2% FBS twice. Cells were
counted and assessed for viability by trypan blue exclusion test on a
Vi-CELL Cell Viability Counter instrument (Beckman Coulter). The
cell suspension was incubated with a PE-conjugated NGFR mono-
clonal antibody (clone ME20.4-1.H4, Miltenyi Biotec) and with
calcein-AM viability marker (Life Technologies) per manufacturers’
recommendations. After incubation, the cell suspension was washed
twice in PBS with 2% FBS. Cells were sorted on a BD FACSAria II
(BD Biosciences) instrument. Unstained and calcein-AM and NGFR-
PE single-color controls were used to set appropriate gates. Cells
high for calcein were gated, and ~1 million NGFRHigh or NGFRLow
cells were sorted into 15-ml conical tubes (Falcon) that were
prepared with 5 ml RMPI 1640 (Corning cellgro) supplemented with
5% FBS and 1% sodium pyruvate (Invitrogen) and plated using
culture conditions described above. FACS-sorted NGFRHigh and
NGFRLow cells were counted using a Countess II FL Automated Cell
Counter (Life Technologies) and cultured for 9 days in fresh growth
media in 96-well plates or treated with vemurafenib for immunoflu-
orescence and growth rate inhibition assays.
In vivo xenograft studies
All animal experiments were conducted in accordance with proce-
dures approved by the Institutional Animal Care and Use Committee
(IACUC) at Harvard Medical School. Six-week-old NU/J mice (Jack-
son Laboratory, Stock# 002019) were transiently anesthetized using
5% vaporized isoflurane and injected subcutaneously in the right
flank with 2.5 × 106 A375 human melanoma cells suspended in
200 ll of growth factor-reduced Matrigel (Corning 356230) in PBS
(1:1). Tumor xenografts were allowed to grow until the mean
volume across the tumors reached 150 mm3 as measured by digital
calipers. Mice were then randomly assigned to treatment (once-
daily) for 5 days with one of the following drug combinations:
Group 1, 200 ll dabrafenib (25 mg/kg) via oral gavage (OG) plus
500 ll JQ1 (50 mg/kg) via intraperitoneal (IP) injection; Group 2,
200 ll of dabrafenib (25 mg/kg) via OG plus 500 ll of IP vehicle
control; Group 3, OG and IP vehicle controls given at equivalent
volumes. Dabrafenib was diluted in 0.5% hydroxypropylmethylcel-
lulose and 0.2% Tween-80 in pH 8.0 distilled water, and JQ1 was
diluted in 5% dextrose in water. After 5 days, mice were transcar-
dially perfused with oxygenated and heparinized Tyrode’s solution;
this allowed for simultaneous euthanasia and exsanguination. Flank
xenografts were then surgically removed and fixed in 4%
paraformaldehyde (PFA) in PBS and stored at 4°C for 48 h. All fixed
tumors from a given treatment group were uniformly paraffin-
embedded into a single paraffin block holder (i.e., 1 block holder
per treatment group) and sectioned at 5 lm thickness: This allowed
each microscope slide bearing a single 5-lm paraffin section to
contain a representative sample of all the tumors from a given
treatment group.
Immunofluorescence staining, quantitation, and analysis
Immunofluorescence assays for cultured cells were performed
using cells seeded in 96-well plates (Corning 3603) and then
treated the next day using Hewlett-Packard (HP) D300 Digital
Dispenser with compounds at reported doses for indicated times in
2–3 replicates. Cells were fixed in 4% paraformaldehyde for
20 min at room temperature and washed with PBS with 0.1%
Tween-20 (Sigma-Aldrich) (PBS-T), permeabilized in methanol for
10 min at room temperature, rewashed with PBS-T, and blocked
in Odyssey blocking buffer (OBB) for 1 h at room temperature.
Cells were incubated overnight at 4°C with primary antibodies in
OBB. Cells were then stained with rabbit, mouse, and goat
secondary antibodies from Molecular Probes (Invitrogen) labeled
with Alexa Fluor 647 (Cat# A31573), Alexa Fluor 488 (Cat#
A21202), and Alexa Fluor 568 (Cat# A11057). Cells were washed
once in PBS-T, once in PBS, and were then incubated in 250 ng/ml
Hoechst 33342 and 1:800 Whole Cell Stain (blue; Thermo
Scientific) solution for 20 min. Cells were washed twice with PBS
and imaged with a 10× objective using a PerkinElmer Operetta
High Content Imaging System. 9–11 sites were imaged in each
well. Image segmentation, analysis, and signal intensity quantita-
tion were performed using Acapella software (PerkinElmer). Popu-
lation-average and single-cell data were analyzed using MATLAB
2014b software. Single-cell density scatter plots were generated
using signal intensities for individual cells.
For immunofluorescence analysis of xenograft and human tumor
sections, processing and staining steps were performed with a custo-
mized protocol using a BOND RX automated immunohistochemistry
processor (Leica Biosystems). Briefly, tissue slides were baked at
60°C for 30 min, de-waxed using Bond Dewax Solution (Leica
Biosystems, Cat# AR9222), antigen retrieved for 20 min using
BOND Epitope Retrieval solution 1 (Leica Biosystems, Cat#
AR9961), and blocked with OBB for 30 min. Slides were incubated
with secondary antibodies (Invitrogen): goat anti-mouse Alexa 647
(Cat# A21236) and goat anti-rabbit Alexa 555 (Cat# A21428) and
scanned with a 10× objective using CyteFinder (RareCyte Inc.) to
obtain pre-staining images for registering background due to non-
specific binding of secondary antibodies (e.g., in necrotic regions of
tumors). Slides were then incubated with a fluorophore inactivating
solution containing 4.5% H2O2 and 20 mM NaOH in PBS for 2 h to
Molecular Systems Biology 13: 905 | 2017 ª 2017 The Authors
Molecular Systems Biology Overcoming adaptive resistance to RAF inhibition Mohammad Fallahi-Sichani et al
20
quench the background fluorescence (Lin et al, 2015). Slides were
then incubated at 4°C overnight with primary antibodies in OBB,
washed with PBS, and stained with the same secondary antibod-
ies described above for 2 h at room temperature. Slides were
re-scanned with a 10× objective using CyteFinder. Images were
stitched together to afford a single aggregate immunofluorescence
image of the whole area of all tumor sections per drug treatment
group. Fluorescence images were flat-field corrected and single-cell
fluorescence intensities were quantified using ImageJ software.
Briefly, the Hoechst channel was used to generate single-cell masks
and ROIs. For Ki-67 nuclear staining, the masks were applied and
the mean/integrated pixel intensity per cell was obtained. For NGFR
staining, the nuclear masks were then converted to ring-shaped
ROIs (2-pixel wide), and the ROIs were applied to quantify NGFR
signal intensities per cell. We then used pre-staining images (gener-
ated from slides stained with secondary antibodies only) to exclude
high-background regions of the tumor (with fluorescence intensities
higher than a separating threshold) from further analysis. Removal
of high-background regions, and analysis of population-average and
single-cell data were performed using MATLAB 2014b software.
Western blots and quantitation
To prepare protein lysates, cells were seeded in 10-cm plates and
treated the next day with either DMSO or two doses of vemu-
rafenib (0.2, 0.32, or 1 lM) for 48 h at 37°C in full growth media.
Cells were transferred to ice, washed with ice-cold PBS, and lysed
with a 1% NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 20 mM
Tris pH 7.5, 10 mM NaF, 1 mM EDTA pH 8.0, 1 mM ZnCl2 pH
4.0, 1 mM MgCl2, 1 mM Na3VO4, 10% glycerol) supplemented
with complete mini/EDTA-free protease inhibitors (Roche, Cat#
11836170001). Protein concentration of cleared lysates was
measured using a BCA assay kit (Thermo Scientific, Cat# 23225).
Lysates were adjusted to equal protein concentrations for each cell
line, 4× NuPage LDS sample buffer (Invitrogen) supplemented with
50 mM DTT was added, and samples were heated for 10 min at
70°C and loaded on Novex 3–8% Tris–Acetate gels (Invitrogen).
Western blots were performed using the iBlot Gel Transfer Stacks
PVDF system (Invitrogen). After blocking with OBB (Licor),
membranes were incubated with primary antibodies diluted
1:1,000 in OBB. As secondary antibody, donkey anti-rabbit IgG
coupled to IRDye 800CW (Licor, Cat# 926-32213) was diluted
1:15,000 in OBB including 0.01% SDS. Membranes were scanned
on an Odyssey CLx scanner (Licor) with 700 and 800 nm channels
set to automatic intensity at a 169 lm resolution. Protein levels
were quantified with the Image Studio 4.0.21 software (Licor)
using the built-in manual analysis tool with a median local back-
ground correction. All intensity values were corrected using the
respective HSP90a/b or b-actin levels and then normalized to the
DMSO control sample for COLO858. Western blots were performed
in three independent replicates, and a representative blot with
quantification is shown.
siRNA transfection
siRNAs against JUN, PTK2, and NGFR genes and a non-targeting
control were from Dharmacon. COLO858 cells seeded in 96-well
plates were transfected using transfection reagent DharmaFECT 2
(Dharmacon) in antibiotic-free growth medium. Cells were treated
the next day with vemurafenib at indicated doses for 48–72 h
followed by fixation for immunofluorescence staining.
Compound screening using a chromatin-targeting library
A375, COLO858, and WM115 cells were plated in two replicates at
4,500, 7,000, and 8,000 cells per well, respectively; cells were
counted using a Countess II FL Automated Cell Counter (Life Tech-
nologies). Cells were treated the next day with either DMSO or three
different doses (0.11, 0.53, and 2.67 lM) of each of 41 compounds
in the Harvard Medical School Library of Integrated Network-based
Cellular Signature (HMS-LINCS) IV chromatin-targeting library (see
https://lincs.hms.harvard.edu/db/libraries/LINCS-IV/ for the list of
compounds) using previously prepared 384-well dilution plates and
a Seiko pin transfer robot system. Immediately after, A375 and
WM115 cells were then treated with 1 lM vemurafenib and
COLO858 cells were treated with 0.32 lM vemurafenib using an HP
D300 Digital Dispenser. Forty-eight hours after treatment, cells were
fixed and analyzed for NGFR expression using immunofluorescence
microscopy, as described earlier. To identify candidate compounds
with potential for suppressing NGFR expression, the NGFR measure-
ments were averaged across the three doses of chromatin-targeting
compounds and z-scored. The data were scatter-plotted between the
two replicates. Compounds whose NGFR levels were consistently
among the five lowest z-scores in all the three cell lines were
selected for further analysis.
Statistical analysis
All data (with error bars) are presented as mean  SD using indi-
cated numbers of replicates. Statistical significance for cell-based
experiments performed at different drug or growth factor doses,
time points, and replicates was determined based on two-way
analysis of variance (ANOVA). Correlation between measurements
was evaluated based on pairwise Pearson’s correlation coefficient.
Statistical significance for xenograft experiments was determined
using the two-tailed two-sample t-test. Significance was set at
P < 0.05. Statistical analyses were performed using MATLAB
2014b software.
Data availability
RNA sequencing data collected in this study were deposited to Gene
Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under
the accession number GSE87641. The data and methods used in this
study are available in a machine-readable format to facilitate re-
analysis by others at https://lincs.hms.harvard.edu/fallahi-sichani-
molsystbiol-2017/.
Expanded View for this article is available online.
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